News | September 09, 2014

TCT 2014 Late-breaking Trials and First Report Investigations

Transcatheter Cardiovascular Therapeutics (TCT) has announced the late-breaking trial presentations at TCT 2014, Sept. 13-17.
 
Late-breaking clinical trials are typically first-time international or U.S. presentations of the primary endpoint or important secondary endpoint results of prospective, randomized clinical trials or presentations of large-scale, impactful single-center or multicenter registries. A first-report investigation is a smaller randomized trial, novel science, or early-human investigation.
 
All presentations will take place in the Main Arena area in the ballroom on level 3.
 
 
Saturday, Sept. 12 — Main Arena I
 
• 11 a.m.— PARTNER I: Five-Year Results From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Balloon-Expandable Device Versus Conservative Care in Extremely High-Risk Patients with Aortic Stenosis. Presented by Samir R. Kapadia.
 
• 11:24 a.m. — U.S. CoreValve High Risk Trial: Cost-Effectiveness Analysis From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Self-Expanding Device Versus Surgical Aortic Valve Replacement in High-Risk Patients with Aortic Stenosis. Presented by Matthew R. Reynolds. 
 
• 11:42 a.m. — CLEAN-TAVI: A Prospective, Randomized Trial of Cerebral Embolic Protection in High-Risk Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. Presented by Axel Linke. 
 
• Noon — The CoreValve US Pivotal Trial: Two-Year Results with a Self-Expanding Bioprosthesis in Extremely High-Risk Patients with Aortic Stenosis. Presented by Steven J. Yakubov.
 
• 12:15 p.m. — ISAR-CLOSURE: A Prospective, Randomized Trial of Two Vascular Closure Devices Versus Manual Compression After Femoral Artery Access. Presented by Stefanie Schulz. 
 
Sunday, Sept. 14 — Main Arena II
 
• 11 a.m. — ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease. Presented by Patrick W. Serruys.
 
• 11:24 a.m. — DKCRUSH-VI: A Prospective, Randomized Trial of FFR-Guided Versus Angiography-Guided Provisional T-Stenting in Patients with True Coronary Bifurcation Lesions. Presented by Shao Liang Chen. 
 
• 11:42 a.m. — RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents. Presented by Fernando Alfonso.
 
Noon — IVUS-CTO: A Prospective, Randomized Trial of Intravascular Ultrasound-Guided Versus Angiography-Guided Drug-Eluting Stent Intervention in Coronary Chronic Total Occlusions. Presented by Yang-Soo Jang.
 
• 12:15 p.m. — OCT STEMI: A Prospective, Randomized Trial of Optical Coherence Tomography Guidance During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. Presented by Pavel Cervinka. 
 
 
Monday, Sept. 15 — Main Arena III
 
• 11:10 a.m. — BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention. Presented by Yaling Han.
 
• 11:30 a.m. — ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation. Presented by Nikolaus Sarafoff. 
 
• 11:48 a.m. — SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation. Presented by
Antonio Colombo. 
 
• 12:06 p.m. — TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. . Presented by Tracy Y. Wang. 
 
• 12:21 p.m. — VELOCITY: A Prospective, Randomized Trial of Peritoneal Hypothermia in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Presented by Gregg W. Stone. 
 
 
Tuesday, Sept. 16 — Main Arena IV
 
• 11 a.m. — PRIMA: A Prospective, Randomized Trial of PFO Closure in Patients with Refractory Migraine with Aura. Presented by David Hildick-Smith.
 
• 11:24a.m. — Symplicity Flex: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Mild Refractory Hypertension. . Presented by Steffen Desch
 
• 11:42 a.m. — EXCITE ISR: A Prospective, Randomized Trial of Excimer Laser Atherectomy Versus Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis.  Presented by Eric J. Dippel. 
 
Noon — I-LOVE-IT 2: A Prospective, Randomized Trial of a Biodegradable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent Versus a Durable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent in Patients with Coronary Artery Disease. Presented by Bo Xu.
 
• 12:15 p.m. — EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease. Presented by Stephane Cook.
 

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init